Key Highlights

  • BioMarin traded at US$55.20, against a consensus target of US$89.52.
  • The median target of US$86 implies roughly +55.8% upside from the current price.
  • Targets span US$60 to US$124, framing the range of analyst opinion.
  • The consensus implies +62.2% upside, reflecting the balance of current analyst views.

BioMarin (NASDAQ:BMRN) traded at US$55.20 as of 8 October 2026, against an analyst consensus price target of US$89.52, an implied upside of approximately +62.2%.

What Is the Latest Analyst Price Target?

The screener, as at 8 October 2026, lists a mean target of $89.52, a median of $86, a low of $60 and a high of $124.

Against the closing price of $55.20 on 8 October 2026, the mean implies potential upside of 62.2% and the median 55.8%. The share price lies below the lowest target, which is $60 and about 8.7% higher.

The mean is above the median by about $3.50, a consequence of the $124 high target, which is roughly 124.6% above the price.

What Are Analysts Saying?

The data provider's consensus is Buy. Individual broker actions, analyst numbers and index membership were not part of this week's verified data set, so none are discussed.

Even without those details, the range tells a clear story. Every target is above the share price, which suggests a market in which forecasters broadly see the shares as undervalued. But the very wide spread signals disagreement about the value of the pipeline and the durability of existing products.

The price-to-earnings ratio of 149.19 is unusually high, though ratios of this sort can be distorted when profits are depressed or affected by one-off items.

What Could Help the Stock Reach the Price Target?

BioMarin has positioned itself as a specialist in therapies for rare genetic conditions, an area where treatments can command high prices and face limited competition. Its portfolio has included enzyme replacement therapies and other medicines for small patient groups.

If analysts prove correct, growth in sales of its established products, successful launches and positive late-stage trial results could all support a higher valuation. Rare-disease franchises often benefit from long treatment durations and strong patient loyalty, so Volume growth can translate into recurring revenue.

Cost discipline and Margin expansion would also matter.

What Could Prevent the Stock Reaching the Target?

Biotechnology carries risks that are quite different from those of most sectors. Clinical Trials can fail, regulators can delay or reject applications, and a single negative result can reshape the Investment case. The share price sitting below even the lowest target hints that the market may already be worried about something.

Competition is also relevant. New therapies, including gene therapies or rival treatments, could reduce Demand for existing products. Pricing and reimbursement pressures from governments and insurers can limit revenue, and Patent expiries expose established medicines to generic or biosimilar rivals.

Valuation adds another layer: at 149.19 times earnings, the shares offer little cushion if profits disappoint. No Dividend is paid, so returns depend wholly on share price movement. Targets are forecasts, and a gap of this size may close slowly or not at all.

What Should Investors Watch Next?

Investors will be watching the next quarterly results and company guidance for product sales, operating margins and spending on research and development. Clinical trial readouts and regulatory decisions are the most important company-specific catalysts and can move the shares sharply.

Progress with new launches, updates on Manufacturing and Supply and any Business development activity should also be tracked.

The Real Story Behind BioMarin's Price Target

BioMarin (BMRN) was priced at US$55.20 against a consensus target of US$89.52, an implied upside of approximately +62.2%. The median target of US$86 and the range of US$60 to US$124 frame the debate among analysts.